<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959490</url>
  </required_header>
  <id_info>
    <org_study_id>CASE14112</org_study_id>
    <secondary_id>NCI-2013-01422</secondary_id>
    <secondary_id>CASE 14112</secondary_id>
    <secondary_id>P30CA043703</secondary_id>
    <nct_id>NCT01959490</nct_id>
  </id_info>
  <brief_title>Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer</brief_title>
  <official_title>Next Generation Sequencing to Evaluate Breast Cancer Subtypes and Genomic Predictors of Response to Therapy in the Preoperative Setting for Stage II-III Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well trastuzumab and pertuzumab or bevacizumab with&#xD;
      combination chemotherapy works in treating patients with stage II-III breast cancer.&#xD;
      Monoclonal antibodies, such as trastuzumab, pertuzumab, and bevacizumab, can block tumor&#xD;
      growth in different ways. Some block the ability of tumors to grow and spread. Others find&#xD;
      tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in&#xD;
      chemotherapy, such as docetaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide,&#xD;
      and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing&#xD;
      the cells or by stopping them from dividing. Giving trastuzumab and pertuzumab or a&#xD;
      commercially marketed formulation of bevacizumab without modification with combination&#xD;
      chemotherapy may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine if genomically derived 'molecular subtypes' predict pathological complete&#xD;
      response to combination chemotherapy and targeted therapy for HER2 early stage breast cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To explore the ability of trastuzumab or pertuzumab response signatures to predict pCR in&#xD;
      HER2 positive tumors treated with brief exposure to trastuzumab or pertuzumab followed by&#xD;
      combination chemotherapy.&#xD;
&#xD;
      II. To explore the value of immune signatures as well as AKT and IGF signatures to predict&#xD;
      pCR in HER2 tumors treated with brief exposure to trastuzumab and pertuzumab.&#xD;
&#xD;
      III. To explore if comprehensive annotation of genomic alterations (mutations, copy number&#xD;
      alternations, gene fusions, non-coding RNA and splice variants) can further sub-stratify&#xD;
      subtype-based classifiers for prediction of response to targeted therapy in early stage&#xD;
      breast cancer IV. To explore if circulating RNA expression levels are associated with&#xD;
      treatment response V. To explore changes in cardiac function and identify early cardiac&#xD;
      injury using strain echocardiograms and cardiac biomarkers during treatment VI. To explore&#xD;
      immunohistochemistry-based markers of response to treatment&#xD;
&#xD;
      Objectives for Imaging Sub-Study: Secondary Objectives I. Evaluate the visualization of&#xD;
      primary breast tumors using analog and digital positron emission tomography (PET) with FDG&#xD;
      and FLT. II. Evaluate the quantification of FDG-uptake in primary breast tumors using analog&#xD;
      and digital PET with FDG and FLT. III. Compare the levels and changes in metabolic tumor&#xD;
      activity from analog and digital FDG-PET/CT or FLT-PET/CT with clinical follow up and other&#xD;
      procures include into CASE 14112 (such as DCE-MRI, genetic testing, etc.)&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 treatment cohorts based on HER2 status.&#xD;
&#xD;
      COHORT I (HER2 positive): Patients receive trastuzumab intravenously (IV) over 30-60 minutes,&#xD;
      and pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment&#xD;
      repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable&#xD;
      toxicity. As part of standard of care, each patient will receive three MRIs pre-treatment,&#xD;
      before biopsy is taken, and before surgery. Ten additional patients will be added to cohort 1&#xD;
      to take part in the imaging sub-study. These ten patients will follow the same procedure as&#xD;
      the other participants in cohort I but will have a PET/CT in place of the DCE-MRI&#xD;
&#xD;
      COHORT II (HER2 negative): Patients receive bevacizumab IV over 30-60 minutes on day 1 of&#xD;
      weeks 1, 3, 5, 7, 9, and 11; doxorubicin IV and cyclophosphamide IV over 30-60 minutes on day&#xD;
      1 of weeks 1, 3, 5, and 7; and paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and&#xD;
      15. Prior to receiving paclitaxel patients will receive the anti-nausea medication&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2013</start_date>
  <completion_date type="Actual">March 29, 2017</completion_date>
  <primary_completion_date type="Actual">November 11, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by Genomically-derived Molecular Subtypes.</measure>
    <time_frame>Up to 30 days after last cycle of treatment</time_frame>
    <description>Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative. pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of HER2 Positive Patients With a Pathological Complete Response (pCR) Predicted by a Trastuzumab and Pertuzumab Response Signature</measure>
    <time_frame>Up to 30 days after last cycle of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of HER2 Negative Patients With a pCR Predicted by the TGF-B Response Signature</measure>
    <time_frame>Up to 30 days after last cycle of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of HER2 Positive Patients With a pCR Predicted by the AKT Signature and IGF Signature.</measure>
    <time_frame>Up to 30 days after last cycle of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients With a pCR Predicated by Copy Number Alterations.</measure>
    <time_frame>Up to 30 days after last cycle of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients With a pCR Predicted by Changes in Texture on Breast DCE-MRI After a Two-week &quot;run-in&quot; Treatment With Trastuzumab, Pertuzumab, or Bevacizumab</measure>
    <time_frame>At 2 weeks after start of run-in period</time_frame>
    <description>Determine if changes in regularity and entropy range predict pCR and in an exploratory fashion determine if specific texture features exist in each molecular subtype that predict pCR.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Descriptive Statistics of PET/CT Scan</measure>
    <time_frame>Up to 30 days after last cycle of treatment</time_frame>
    <description>Qualitative and quantitative image analysis will be performed and descriptively summarized. For the 10 patients in the PET/CT sub-study of cohort 1.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1P (HER2 positive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1T (HER2 positive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort II (HER2 negative)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort 1P (HER2 positive)</arm_group_label>
    <arm_group_label>Cohort 1T (HER2 positive)</arm_group_label>
    <other_name>anti-c-erB-2</other_name>
    <other_name>Herceptin</other_name>
    <other_name>MOAB HER2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort 1P (HER2 positive)</arm_group_label>
    <arm_group_label>Cohort 1T (HER2 positive)</arm_group_label>
    <other_name>2C4</other_name>
    <other_name>Perjeta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort 1P (HER2 positive)</arm_group_label>
    <arm_group_label>Cohort 1T (HER2 positive)</arm_group_label>
    <other_name>RP 56976</other_name>
    <other_name>Taxotere</other_name>
    <other_name>TXT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort 1P (HER2 positive)</arm_group_label>
    <arm_group_label>Cohort 1T (HER2 positive)</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort II (HER2 negative)</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>doxorubicin hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort II (HER2 negative)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort II (HER2 negative)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Cohort II (HER2 negative)</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the breast, with sufficient tissue&#xD;
             available for estrogen receptor (ER), progesterone receptor (PR), and HER 2 testing&#xD;
&#xD;
               -  HER2 must be positive by IHC or ISH testing by laboratory standard.&#xD;
&#xD;
          -  Needle biopsy or incisional biopsy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1&#xD;
&#xD;
          -  Resectable disease-clinical stage I (T/0/N0miT1N0-N0mi), IIA-IIIA (T2 N0/T3N0 or T1-3&#xD;
             N1-N2a) or unresectable disease - clinical stage IIIB/IIIC (T4 or T1-3 N2b-3); no&#xD;
             evidence of metastatic disease&#xD;
&#xD;
          -  No prior chemotherapy, hormonal therapy, or radiation therapy for this cancer&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1000/ul&#xD;
&#xD;
          -  Platelet count ≥ 100,000/ul&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dl&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 mg/dl or measured creatinine clearance of &gt; 30 ml/min&#xD;
&#xD;
          -  Total bilirubin ≤ upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) ≤ 2.5 x ULN&#xD;
&#xD;
          -  Patients with multiple foci of invasive cancer in the same breast are eligible if any&#xD;
             single lesion meets the above size criteria and all sampled lesions are histologically&#xD;
             similar (whether radiographically detected lesions separate from the target lesion are&#xD;
             sampled for histologic evaluation is left to the discretion of the treating&#xD;
             physicians); the presence of ductal carcinoma in situ (DCIS) or lobular carcinoma in&#xD;
             situ (LCIS) in either breast will not render a patient ineligible; patients with a&#xD;
             small focus of invasive cancer detected the contralateral breast (clinical T1N0) are&#xD;
             eligible, however only the histologic response in the breast containing the target&#xD;
             lesions will be considered in determining the patient's pathologic response&#xD;
&#xD;
          -  Measurable disease in the breast or axilla that measures at least 1 cm by either&#xD;
             clinical or radiographic measurement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Excisional biopsy&#xD;
&#xD;
          -  Pregnant and lactating women are not eligible; all participants of reproductive age&#xD;
             must have a negative serum pregnancy test at baseline and agree to use an effective&#xD;
             barrier method of contraception during the entire period of treatment on the study&#xD;
&#xD;
          -  Patients with New York Heart Association (NYHA) grade 2 or higher congestive heart&#xD;
             failure, myocardial infarction within the last 6 months, unstable angina pectoris, or&#xD;
             arterial thrombotic event with the past 12 months, uncontrolled hypertension (systolic&#xD;
             blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 on antihypertensive&#xD;
             medications; patients not on medication for high blood pressure who are found to have&#xD;
             systolic blood pressure [SBP] &gt; 150 and/or diastolic blood pressure [DBP] &gt; 100 should&#xD;
             have 3 documented episodes of elevated blood pressure before being considered&#xD;
             'uncontrolled', if they have 3 documented episodes of elevated blood pressure, then&#xD;
             can be started on antihypertensive medications; patients currently on antihypertensive&#xD;
             medications with elevated blood pressures as defined above may have their medications&#xD;
             adjusted; if patients have persistent [3 episodes] of high blood pressure despite&#xD;
             medication adjustment they will be considered ineligible for study participation; each&#xD;
             measured episode should be 24 hours apart), prior history of hypertensive crisis or&#xD;
             hypertensive encephalopathy, uncontrolled or clinically significant arrhythmia, grade&#xD;
             II or greater peripheral vascular disease or prior history of stroke or transient&#xD;
             ischemic attack (TIA); patient must have a pretreatment multi gated acquisition scan&#xD;
             (MUGA) scan or echocardiogram with left ventricular ejection fraction (LVEF) above&#xD;
             lower limit of normal&#xD;
&#xD;
          -  No non-breast malignancy within the past 5 years other than treated squamous or basal&#xD;
             cell carcinoma of the skin or CIS of the cervix&#xD;
&#xD;
          -  Patients known to be human immunodeficiency virus (HIV) positive are not eligible for&#xD;
             the study given their potentially compromised immune systems and increased risk of&#xD;
             treatment-related toxicity&#xD;
&#xD;
          -  Advanced (T1N1-4/T2-3 N any) invasive cancer in the contralateral breast&#xD;
&#xD;
          -  Any known history of cerebrovascular disease including TIA, stroke or subarachnoid&#xD;
             hemorrhage&#xD;
&#xD;
          -  Patients must not have a non-healing wound or fracture&#xD;
&#xD;
          -  Patients with an abdominal fistula, gastrointestinal perforation, or intra-abdominal&#xD;
             abscess within 6 months&#xD;
&#xD;
          -  Patients must not have a bleeding diathesis, hereditary of acquired bleeding disorder&#xD;
             or coagulopathy&#xD;
&#xD;
          -  Patients on therapeutic doses of Coumadin or Lovenox are ineligible to participate in&#xD;
             study&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to study enrollment or anticipation of need for major surgical procedure during&#xD;
             the course of the study; core biopsy or other minor surgical procedure, for example&#xD;
             placement of a vascular access device, are excluded from this requirement&#xD;
&#xD;
          -  No known hypersensitivity to any component of bevacizumab&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Silverman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 16, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <results_first_submitted>January 8, 2019</results_first_submitted>
  <results_first_submitted_qc>February 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2019</results_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1P (HER2 Positive)</title>
          <description>Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1T (HER2 Positive)</title>
          <description>Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P3">
          <title>Cohort II (HER2 Negative)</title>
          <description>Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks&#xD;
1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants enrolled in study</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1P (HER2 Positive)</title>
          <description>Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1T (HER2 Positive)</title>
          <description>Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Cohort II (HER2 Negative)</title>
          <description>Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>30-39 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>40-49 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>50-59 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>60-69 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>70-79 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by Genomically-derived Molecular Subtypes.</title>
        <description>Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative. pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy.</description>
        <time_frame>Up to 30 days after last cycle of treatment</time_frame>
        <population>All participants enrolled in study and who received treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1P (HER2 Positive)</title>
            <description>Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1T (HER2 Positive)</title>
            <description>Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Cohort II (HER2 Negative)</title>
            <description>Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks&#xD;
1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by Genomically-derived Molecular Subtypes.</title>
          <description>Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative. pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy.</description>
          <population>All participants enrolled in study and who received treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of HER2 Positive Patients With a Pathological Complete Response (pCR) Predicted by a Trastuzumab and Pertuzumab Response Signature</title>
        <time_frame>Up to 30 days after last cycle of treatment</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1P (HER2 Positive)</title>
            <description>Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1T (HER2 Positive)</title>
            <description>Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Cohort II (HER2 Negative)</title>
            <description>Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks&#xD;
1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of HER2 Positive Patients With a Pathological Complete Response (pCR) Predicted by a Trastuzumab and Pertuzumab Response Signature</title>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of HER2 Negative Patients With a pCR Predicted by the TGF-B Response Signature</title>
        <time_frame>Up to 30 days after last cycle of treatment</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1P (HER2 Positive)</title>
            <description>Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1T (HER2 Positive)</title>
            <description>Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Cohort II (HER2 Negative)</title>
            <description>Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks&#xD;
1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of HER2 Negative Patients With a pCR Predicted by the TGF-B Response Signature</title>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of HER2 Positive Patients With a pCR Predicted by the AKT Signature and IGF Signature.</title>
        <time_frame>Up to 30 days after last cycle of treatment</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1P (HER2 Positive)</title>
            <description>Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1T (HER2 Positive)</title>
            <description>Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Cohort II (HER2 Negative)</title>
            <description>Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks&#xD;
1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of HER2 Positive Patients With a pCR Predicted by the AKT Signature and IGF Signature.</title>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients With a pCR Predicated by Copy Number Alterations.</title>
        <time_frame>Up to 30 days after last cycle of treatment</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1P (HER2 Positive)</title>
            <description>Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1T (HER2 Positive)</title>
            <description>Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Cohort II (HER2 Negative)</title>
            <description>Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks&#xD;
1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients With a pCR Predicated by Copy Number Alterations.</title>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients With a pCR Predicted by Changes in Texture on Breast DCE-MRI After a Two-week &quot;run-in&quot; Treatment With Trastuzumab, Pertuzumab, or Bevacizumab</title>
        <description>Determine if changes in regularity and entropy range predict pCR and in an exploratory fashion determine if specific texture features exist in each molecular subtype that predict pCR.</description>
        <time_frame>At 2 weeks after start of run-in period</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1P (HER2 Positive)</title>
            <description>Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1T (HER2 Positive)</title>
            <description>Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Cohort II (HER2 Negative)</title>
            <description>Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks&#xD;
1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients With a pCR Predicted by Changes in Texture on Breast DCE-MRI After a Two-week &quot;run-in&quot; Treatment With Trastuzumab, Pertuzumab, or Bevacizumab</title>
          <description>Determine if changes in regularity and entropy range predict pCR and in an exploratory fashion determine if specific texture features exist in each molecular subtype that predict pCR.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Descriptive Statistics of PET/CT Scan</title>
        <description>Qualitative and quantitative image analysis will be performed and descriptively summarized. For the 10 patients in the PET/CT sub-study of cohort 1.</description>
        <time_frame>Up to 30 days after last cycle of treatment</time_frame>
        <population>Outcome not determined because low accrual prevented appropriate analysis and calculation of the prediction measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1P (HER2 Positive)</title>
            <description>Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1T (HER2 Positive)</title>
            <description>Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Cohort II (HER2 Negative)</title>
            <description>Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks&#xD;
1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Descriptive Statistics of PET/CT Scan</title>
          <description>Qualitative and quantitative image analysis will be performed and descriptively summarized. For the 10 patients in the PET/CT sub-study of cohort 1.</description>
          <population>Outcome not determined because low accrual prevented appropriate analysis and calculation of the prediction measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 30 days after last cycle of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1P (HER2 Positive)</title>
          <description>Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1T (HER2 Positive)</title>
          <description>Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E3">
          <title>Cohort II (HER2 Negative)</title>
          <description>Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks&#xD;
1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="7" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Paula Silverman</name_or_title>
      <organization>Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</organization>
      <phone>1-800-641-2422</phone>
      <email>CTUreferral@UHhospitals.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

